Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients

The University of Alabama at Birmingham, Birmingham, AL, USA.
The Pediatric Infectious Disease Journal (Impact Factor: 2.72). 02/2009; 28(2):159-61. DOI: 10.1097/INF.0b013e3181861d8b
Source: PubMed


The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m twice daily and efavirenz (EFV) 350 mg/m once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m may not be sufficient.

6 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Significant advances have been made in the treatment of human immunodeficiency virus (HIV) infection over the past two decades. Improved therapy has prolonged survival and improved clinical outcome for HIV-infected children and adults. Sixteen antiretroviral (ART) medications have been approved for use in pediatric HIV infection. The Department of Health and Human Services (DHHS) has issued "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection", which provide detailed information on currently recommended antiretroviral therapies (ART). However, consultation with an HIV specialist is recommended as the current therapy of pediatric HIV therapy is complex and rapidly evolving.
    Therapeutics and Clinical Risk Management 07/2009; 5(3):469-84. DOI:10.2147/TCRM.S4594 · 1.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Because of the lack of a lopinavir/ritonavir (LPV/r) pediatric formulation, 54 HIV-infected children were given generic LPV/r adult tablets. Of 54 children, 21 took cut pills to get the appropriate dose. The median (interquartile range) LPV trough serum concentration (C trough) was 6.7 (5.0-9.9) mg/L. All the children had C trough >1.0 mg/L and 96% had values >4.0 mg/L. LPV/r adult tablets can be used in children when it is necessary.
    The Pediatric Infectious Disease Journal 10/2009; 29(1):79-82. DOI:10.1097/INF.0b013e3181b21040 · 2.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: No formal comparison has been made between the pediatric post-highly active antiretroviral therapy (HAART) outcomes of resource-limited and developed countries. To systematically quantify and compare major baseline characteristics and clinical end points after HAART between resource-limited and developed settings. Published articles and abstracts (International AIDS Society 2009, Conference on Retroviruses and Opportunistic Infections 2010) were examined from inception (first available publication for each search engine) to March 2010. Publications that contained data on post-HAART mortality, weight-for-age z score (WAZ), CD4 count, or viral load (VL) changes in pediatric populations were reviewed. Selected studies met the following criteria: (1) patients were younger than 21 years; (2) HAART was given (≥ 3 antiretroviral medications); and (3) there were >20 patients. Data were extracted for baseline age, CD4 count, VL, WAZ, and mortality, CD4 and virologic suppression over time. Studies were categorized as having been performed in a resource-limited country (RLC) or developed country (DC) on the basis of the United Nations designation. Mean percentage of deaths per cohort and deaths per 100 child-years, baseline CD4 count, VL, WAZ, and age were calculated for RLCs and DCs and compared by using independent samples t tests. Forty RLC and 28 DC publications were selected (N = 17 875 RLCs; N = 1835 DC). Mean percentage of deaths per cohort and mean deaths per 100 child-years after HAART were significantly higher in RLCs than DCs (7.6 vs 1.6, P < .001, and 8.0 vs 0.9, P < .001, respectively). Mean baseline CD4% was 12% in RLCs and 23% in DCs (P = .01). Mean baseline VLs were 5.5 vs 4.7 log(10) copies per mL in RLCs versus DCs (P < .001). Baseline CD4% and VL differ markedly between DCs and RLCs, as does mortality after pediatric HAART. Earlier diagnosis and treatment of pediatric HIV in RLCs would be expected to result in better HAART outcomes.
    PEDIATRICS 02/2011; 127(2):e423-41. DOI:10.1542/peds.2009-2701 · 5.47 Impact Factor
Show more

Similar Publications


6 Reads
Available from